Article Text

PDF

Clinical hepatology
P03 The use of BRUM1 resequencing microarray to identify mutations in patients with neonatal cholestasis
  1. J Hartley,
  2. C Bruce,
  3. R Brown,
  4. K McKay,
  5. U Bauman,
  6. E Sturm,
  7. B Udd,
  8. P Mckiernan,
  9. D McMullen,
  10. J Mansson,
  11. F McDonald,
  12. E Maher,
  13. A Knisely,
  14. C Hendriksz,
  15. D Kelly,
  16. P Gissen
  1. Liver Unit, Birmingham Children's Hospital, UK

Abstract

Introduction Neonatal cholestasis is the presenting clinical feature of serious and potentially life limiting liver diseases such as progressive familial intrahepatic cholestasis (PFIC), arthrogryposis-renal-cholestasis (ARC) syndrome and Niemann Pick C (NPC) disease. A single rapid molecular test to confirm the diagnosis would reduce the delay from molecular genetic investigation at multiple diagnostic centres thus facilitating optimal clinical management and counselling. We have designed a resequencing microarray (BRUM1) capable of simultaneously sequencing multiple genes associated with neonatal cholestasis.

Aim To assess the utility of BRUM1 as a first-line molecular investigation for patients with neonatal cholestasis in whom an inherited causes is suspected.

Method DNA from 95 infants with neonatal cholestasis in whom an inherited cause was suspected was amplified by PCR and hybridised to BRUM1 (validated against reference sequencing with 98.9% agreement (CI 0.97 to >0.99)) for simultaneous sequencing of the main causes of inherited disease in this group which included ATP8B1, ABCB11, ABCB4, VPS33B, VIPAR, NPC1 and NPC2. Children with known α-1 antitrypsin deficiency or Alagille syndrome were not included.

Results 30 infants had pathogenic mutations, which cause neonatal cholestasis. 23 of the mutations were novel.

GeneTotal number of mutationsNovel mutations
ATP8B161
ABCB111110
ABCB421
VPS33B54
VIPAR22
NPC1174
NPC211
Abstract P03 Table 1

Results

In this cohort of patients, 30.5% of infants with neonatal cholestasis had a genetic diagnosis confirmed by BRUM1. The average time to diagnosis was 5–25 days.

Conclusion A specific and rapid genetic diagnosis in infants with a phenotype of neonatal cholestasis can be made using a single resequencing microarray, to optimise clinical management and facilitate appropriate counselling of families.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.